KR20240005839A - 인간화 항체를 포함한 시약 - Google Patents

인간화 항체를 포함한 시약 Download PDF

Info

Publication number
KR20240005839A
KR20240005839A KR1020237041539A KR20237041539A KR20240005839A KR 20240005839 A KR20240005839 A KR 20240005839A KR 1020237041539 A KR1020237041539 A KR 1020237041539A KR 20237041539 A KR20237041539 A KR 20237041539A KR 20240005839 A KR20240005839 A KR 20240005839A
Authority
KR
South Korea
Prior art keywords
antibody
humanized
antibodies
crp
humanized antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237041539A
Other languages
English (en)
Korean (ko)
Inventor
하루토 이시카와
키미타카 야마모토
노리유키 이즈타니
다이스케 오가사와라
유키 와카바야시
Original Assignee
덴카 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 덴카 주식회사 filed Critical 덴카 주식회사
Publication of KR20240005839A publication Critical patent/KR20240005839A/ko
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020237041539A 2021-07-26 2022-07-26 인간화 항체를 포함한 시약 Pending KR20240005839A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2021-121812 2021-07-26
JP2021121812 2021-07-26
PCT/JP2022/028698 WO2023008404A1 (ja) 2021-07-26 2022-07-26 ヒト化抗体を含む試薬

Publications (1)

Publication Number Publication Date
KR20240005839A true KR20240005839A (ko) 2024-01-12

Family

ID=85086990

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237041539A Pending KR20240005839A (ko) 2021-07-26 2022-07-26 인간화 항체를 포함한 시약

Country Status (7)

Country Link
US (1) US20250102496A1 (https=)
EP (1) EP4372009A4 (https=)
JP (1) JPWO2023008404A1 (https=)
KR (1) KR20240005839A (https=)
CN (1) CN117716037A (https=)
TW (1) TW202311743A (https=)
WO (1) WO2023008404A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025135074A1 (ja) * 2023-12-18 2025-06-26 デンカ株式会社 標的抗原の測定方法並びにそれに用いる抗体、不溶性粒子及び標的抗原測定用キット

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008249738A (ja) 2008-07-18 2008-10-16 Eiken Chem Co Ltd 免疫反応干渉物質の除去方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07260786A (ja) * 1994-03-18 1995-10-13 Tosoh Corp ヒト由来一定領域を有する抗体を使用する免疫測定方法
WO2005058359A2 (en) * 2003-12-15 2005-06-30 Theralogic Gmbh & Co. Kg Method for neutralizing effects of crp for increasing immune reactions to hiv
ES2595638T3 (es) * 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
KR20110112307A (ko) * 2008-11-25 2011-10-12 앨더 바이오파마슈티컬즈, 인코포레이티드 알부민을 상승시키고 및／또는 ｃｒｐ를 낮추는 ｉｌ­６의 길항제
ES2871648T7 (es) 2014-09-17 2024-10-16 Univ Cornell Identificación del estado de la fertilidad masculina mediante la determinación de la capacitación del esperma
CA3013522A1 (en) * 2016-02-05 2017-08-10 Dana Genetic A/S Method for diagnosing and treating cancer using antibodies that bind to c1 inactivator, c reactive protein and/or complement component c4

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008249738A (ja) 2008-07-18 2008-10-16 Eiken Chem Co Ltd 免疫反応干渉物質の除去方法

Also Published As

Publication number Publication date
US20250102496A1 (en) 2025-03-27
JPWO2023008404A1 (https=) 2023-02-02
TW202311743A (zh) 2023-03-16
WO2023008404A1 (ja) 2023-02-02
EP4372009A1 (en) 2024-05-22
EP4372009A4 (en) 2025-06-11
CN117716037A (zh) 2024-03-15

Similar Documents

Publication Publication Date Title
US11372001B2 (en) Anti-human IgG4 monoclonal antibody and methods of making and using same
KR20070108284A (ko) Ｃ형 간염 바이러스의 검출 방법
KR20240005839A (ko) 인간화 항체를 포함한 시약
EP1777524B1 (en) Chimera of human IgE receptor alpha-chain and avian constant immunoglobulin domains for the determination of serum IgE
Gautam et al. Immunoglobulin-M purification—Challenges and perspectives
CN119490593B (zh) 一种抗κ型轻链抗体及其应用
CN119490592B (zh) 一种抗κ型轻链抗体及其应用
JP2021524483A (ja) Ｅ型肝炎ウイルスのＯＲＦ２ｉタンパク質に対する特異性を有する抗体及び診断目的のためのその使用
KR102767384B1 (ko) 마이코플라즈마 뉴모니에의 면역 측정 방법 및 면역 측정 기구
KR102569269B1 (ko) 피검 대상의 검출 방법 및 그것을 위한 면역 측정 기구 및 모노클로널 항체
JP7626753B2 (ja) Ｆｃ領域の一部を欠損した抗体を含む試薬
JP7212682B2 (ja) カンピロバクター属の細菌の検出のための抗体および試験デバイス
JP7834214B2 (ja) 標的抗原の測定方法並びにそれに用いる不溶性粒子及び標的抗原測定用キット
Phillips Affinity chromatography in antibody and antigen purification
JP7366411B2 (ja) ヒトαディフェンシンＨＤ５を検出する方法及びキット、並びにこれらにおいて用いられる抗体
TW201915016A (zh) 單株抗體或其抗原結合片段及其用途
JP2024026911A (ja) 標的抗原の測定方法並びにそれに用いる不溶性粒子及び標的抗原測定用キット
CN121285662A (zh) 高通量Fab抗体片段生成和排序
WO2023238821A1 (ja) 抗ミオグロビンモノクローナル抗体
CN119505004A (zh) 抗rf的抗体或其功能性片段及其应用
CN119431580A (zh) 一种抗人tigit单克隆抗体及其应用
CN120958022A (zh) 用于获得具有高亲和力的抗体分子的方法
CN120775055A (zh) 一种抗泛种特异性抗原疟原虫乳酸脱氢酶的抗体及其应用
Smejkal et al. Separations in proteomics: use of camelid antibody fragments in the depletion and enrichment of human plasma proteins for proteomics applications
HK40031146B (zh) 抗人igg4单克隆抗体及利用该抗体的人igg4测定试剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902